Amgen is getting the ball rolling on a far-reaching new partnership that’s set to boost its profile in its hometown of ...

With T-cell engagers already established as late-line therapies for certain blood cancers, Regeneron has released early data ...

Nineteen novel drugs have been selected for inclusion in the first iteration of China's Commercial Health Insurance Innovative Drug Catalogue, portending potential access benefits as the program ga | ...

UCB plans to file for regulatory approval of Fintepla to treat a third epileptic condition “as soon as possible,” the company ...

Three years after introducing Hemgenix, the first gene therapy for hemophilia B, CSL Behring has released long-term data ...

Pfizer has unveiled phase 3 results that could help the company’s hemophilia drug Hympavzi level the playing field in its ...

In the U.S., receiving healthcare depends on information changing hands. And that’s not just for patients undergoing ...

After many months of uncertainty related to the Biosecure Act and associated security efforts in Washington, D.C., Chinese ...

The FDA is investigating a safety signal from Takeda’s rare disease med Adzynma. Otsuka won a first-in-class FDA approval to ...

Halozyme is seeing some progress in its global effort to defend intellectual property against alleged infringement by Merck & ...

Cosmo Pharmaceuticals has revealed topline results from two phase 3 trials which indicate that its topical cream clascoterone ...

Drastic overhauls of U.S. vaccine regulations proposed by top FDA official Vinay Prasad, M.D., have drawn harsh pushback from ...